NEVERMINED-AG
12.7.2022 15:02:09 CEST | Business Wire | Press release
Nevermined AG , a Web3 company that provides tools to read, write and own your digital assets, announced their initial investment round of €3 million, co-led by Signature Ventures and Polymorphic Capital. The Nevermined platform consists of modular solutions that easily allow users the ability to create and monetize digital assets and participate in the read-write-own vision of Web3.
The platform offers the foundations for building digital ecosystems with components like Tokenization Engine, Marketplace Creator, Royalties Engine, Decentralized Access Control, DAO Framework and DISC, or Data In-Situ Computation, for Remote Computation.
Nevermined CEO Don Gossen shares, “The best internet is the one that everyone can access and own. And this is what Nevermined allows people to do. When it comes to Data mixed with Web3 our pedigree speaks for itself – our team has been working with cutting-edge tech for over 20 years, first in Big Data, and now in Web3. With these building blocks, we can help you realize your vision. I’d argue we’re the best team in the world that does what we do.”
According to a new report by Grand View Research , the global blockchain technology market size is expected to reach $1,431 billion by 2030. With this market opportunity and its solid, proven technology, Nevermined will leverage this capital raise to:
Be more complete and scalable by advancing its product roadmap: Nevermined will enhance its digital asset development platform that makes Web3 accessible by streamlining the creation, monetization and management of decentralized digital assets. Some key projects include:
- Enterprise: A global energy company used the platform to create a peer-to-peer carbon certificate trading marketplace.
- Creative: Autonomies is using Nevermined to build a music NFT platform and DAO, allowing for fairer value distribution between musicians, labels and collectors.
- Science: In a world first, VitaDAO used Nevermined to tokenize the IP of scientific research, conducted by the Scheibye-Knudsen Lab in Copenhagen.
Be more accessible by accelerating global footprint: To foster company growth and better customer experience, Nevermined will be strengthening its presence in key areas including product, engineering, marketing and community.
Be easier to use by expanding the breadth and depth of the partner ecosystem: Nevermined will establish both technical and creative partnerships that will bolster its mission. Along with deepening partnerships with initiatives such as Autonomies , a music NFT platform allowing artists to become stakeholders.
“We only invest in outstanding teams that build the backbone of the decentralized future,'' said Managing Director Juliane Hahn, Signature. “We see many startups that try to combine Data with Blockchains. Nevermined is the first company that understands the complexities and provides actual solutions at the intersection of Data and Web3. In the future every data-driven company will require the ability to turn their data silos into data ecosystems. Nevermined delivers the full product stack to do just that.”
“We’ve been very impressed with the Nevermined team,” said Vitaly Spassky, founder of Polymorphic Capital. “They have the vision, as well as the tech talent and pedigree to execute. To us digital assets are a crucial building block for the decentralized web. And the Nevermined platform makes it super easy for teams and projects to integrate Web3 tech. We’re very excited to see what people will build with Nevermined.”
Nevermined began as an incubation project within Keyko AG to solve issues around data sharing using tokenization and smart contract gateways. From there it evolved from a data-centric solution to a decentralized digital assets solution with much broader applicability.
About Nevermined
Nevermined is a Web3 company that provides tools to read, write and own your digital assets, founded by CEO Don Gossen, CTO Aitor Argomaniz and CIO Dimitri De Jonghe. They met while creating Ocean Protocol, the world’s first decentralized data marketplace. In 2019, they founded Keyko over a shared belief in the power of digital ecosystems. They helped a variety of organizations develop Web3 ecosystems, worth a combined value of $3 billion. In 2022, they decided to spin out Nevermined as a standalone technology platform.
More info on https://nevermined.io/
About Signature Ventures
Signature Ventures is an early-stage Venture Capital fund investing in Blockchain, Distributed Ledger Technology and Web3 technology. Based in Germany, the fund invests in Pre-Seed to Series A, globally with a focus on Europe. Signature Ventures is managed by Juliane Hahn, Founding Partner, and Dr. Georg Stricker, Tech Partner. They combine an extensive track record of VC investments with deep Blockchain expertise.
About Polymorphic Capital
Polymorphic Capital is a venture capital firm that invests globally in teams creating the future of the internet with decentralized protocols and digital assets. They specialize in infrastructure, finance and gaming.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220712005503/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings30.8.2026 14:23:00 CEST | Press release
–Late-Breaking Prespecified Subgroup Analysis of HELIOS-B Demonstrates that Vutrisiran Provided Consistent Clinical Benefit Across All-Cause Mortality and Recurrent Cardiovascular Events in Patients With or Without Tafamidis Use at Baseline ––Additional Post Hoc Analyses Highlight Positive Impact of Vutrisiran in Addressing the Multisystemic Manifestations of ATTR-CM ––Pooled Analysis Across Four Positive Phase 3 Studies of Vutrisiran and Patisiran Shows Consistent Treatment Effect Across Sexes ––New Subgroup Analysis from KARDIA-3 Phase 2 Study of Zilebesiran Highlights Potential to Provide Enhanced Blood Pressure Control – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the European Society of Cardiology (ESC) Congress 2026 demonstrating the strength of RNAi-powered silencing for cardiovascular disease. The findings further reinforce the clinical profile of AMVUTTRA® (vutrisiran) across transthyretin amyloidosis (ATTR)
New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202629.8.2026 23:54:00 CEST | Press release
Qarmousha Pure Ultra White falcon sells for AED 1.5 million at the Abu Dhabi International Hunting and Equestrian Exhibition 2026 (ADIHEX) falcon auction Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release
MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom